Iris Scheffen

Statistics

Publications

Citations

H-Index

Active since

2022

Affiliations

Rotkreuzklinikum München(Current)

Deutsches Archäologisches Institut, Zentrale

Charité - Universitätsmedizin Berlin

Ludwig-Maximilians-Universität München

Medizinische Hochschule Hannover

Iris Scheffen is an author at Rotkreuzklinikum München specializing in chemotherapy, hormone receptor-positive breast cancer therapy, and immunotherapy.

Publications per year

2022–2023

Publications

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Nadia Harbeck, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2023 · 35 citations

Medicine, Oncology, Pharmacotherapy +17

Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype

Sherko Küemmel, Oleg Gluz, Mattea Reinisch et al. · Cancer Research · 2022 · 10 citations

Medicine, Immunology, Oncology +17

1–2 of 2